… NSCLC patients. In addition, several clinical studies indicated that erlotinib could confer
benefits in certain patients with NSCLC after gefitinib failure [18, 19]. Thus, erlotinib may have a …

… for men and patients with squamous cell histology. … cell non–small-cell lung cancer derived
a significant survival benefit from erlotinib (HR, 0.66; P = 0.015) despite a very low tumor …

… Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …

… (TKI) erlotinib has been at the forefront of changes in treatment practice for advanced non–small
cell lung cancer (NSCLC) over the past 10 years. Erlotinib was initially approved for use …

… The MTD of the combination of crizotinib and erlotinib in patients with advanced NSCLC
was crizotinib, 150 mg twice daily, with erlotinib, 100 mg once daily, which is less than the …

… erlotinib for non-small cell lung cancer (NSCLC), we performed a population-based observational
study. The study involved 307 patients treated with erlotinib … The tumor response and …

… Preclinical studies have suggested that erlotinib at high doses may inhibit additional …
erlotinib administered on a weekly schedule to patients with advanced nonsmall cell lung cancer …

… objective: Erlotinib is one of the standard second/third line treatments for patients with
advanced non-small cell lung cancer (NSCLC). This study investigated the efficacy of erlotinib in a …

… nonsmall-cell lung cancer (NSCLC), dacomitinib showed improved PFS compared with
erlotinib in … This led to a phase III study of dacomitinib versus erlotinib in patients with advanced …

… Erlotinib, an epidermal growth factor receptor (EGFR) … in unselected patients with advanced
non–small cell lung cancer (… predict which patients will obtain clinical benefit from erlotinib. …